On May 1, 2018 CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, reported its first quarter 2018 financial results on Wednesday, May 9, 2018, after the NASDAQ market close (Press release, CytomX Therapeutics, MAY 1, 2018, View Source;p=RssLanding&cat=news&id=2346043 [SID1234525909]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company will not be conducting a conference call in connection with this financial results press release.

On May 1, 2018 Sangamo Therapeutics, Inc. (Nasdaq: SGMO) reported that the company will release its first quarter 2018 financial results before the market opens on Tuesday, May 8, 2018 (Press release, Sangamo Therapeutics, MAY 1, 2018, View Source [SID1234525926]). The press release will be followed by a conference call at 8:00 a.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review its financial results and provide a business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. The conference ID number for the call is 1194369. Participants may access the live webcast via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. A conference call replay will be available for one week following the conference call. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 1194369.

On May 1, 2018 Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, reported that Richard Murray, Ph.D., chief executive officer and president of Jounce, will present at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 1:30 PM ET in Boston, MA (Press release, Jounce Therapeutics, MAY 1, 2018, View Source;p=RssLanding&cat=news&id=2345890 [SID1234525886]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available by visiting "Events and Presentations" in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcast will be archived for 30 days following the presentation.

On May 1, 2018 Diplomat Pharmacy, Inc. (NYSE: DPLO), reported that executives will attend the 43rd Annual Deutsche Bank Health Care Conference in Boston (Press release, Diplomat Speciality Pharmacy, MAY 1, 2018, View Source [SID1234525910]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interim CEO Jeff Park, President Joel Saban, and Chief Financial Officer Atul Kavthekar are scheduled to present at 12:50 p.m. ET Wednesday, May 9.

A live audio-only webcast of the presentation and related materials will be available on the investor relations section of Diplomat’s website at ir.diplomat.is. The webcast and presentation materials will be online for 90 days.

On May 1, 2018 Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immunogenicity, reported that members of the Selecta management team will present at the following investor conferences (Press release, Selecta Biosciences, MAY 1, 2018, View Source [SID1234525928]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 43rd Annual Deutsche Bank Health Care Conference – 1.30 p.m. ET on Tuesday, May 8, 2018 in Boston.
UBS Global Healthcare Conference – 9:00 a.m. ET on Wednesday, May 23, 2018 in New York City.
Live and archived webcasts of the presentations will be available on the Investors & Media section of the Selecta website at www.selectabio.com.